Research projects

ExofluidTT aims to provide a new approach for the treatment of diseases where it is essential to direct the therapy locally, such as cancer. However, after decades of research,  the naovectors developed are not efficient enough for targeted therapies. Among the causes of the low efficiency in addressing the target cells are: opsonization, the formation of the protein corona, the difficulty to be interlized in cell membranes or the reduced circulation time. All of these causes occur because the materials used to produce these vectors are not advanced enough for selective targeting. It is for this reason that Exofluid TT is using extracellular vesicles (exosomes) generated by the cells themselves and whose structure and composition is so complex that its production by synthetic procedures is not feasible yet as a therapeutic vectors. These vesicles are nanometric in size and although the application of these vesicles is being a revolution in cell treatments, since they make it possible to deal with the problems in which artificial nanovectors fail, their clinical use is complex due to the difficulty in their production, isolation and reconfiguration for the treatment of diseases such as cancer. It is in this regard that ExoFluidTT is developing different procedures to engineer these vesicles to subsequent therapeutic uses through selective growth inside of functional nanoparticles. The results obtained are very relevant, obtaining the following advances: 1) Gold nanoparticles absorbing NIR radiation have been encapsulated inside the exosomes. The exosome has managed to direct these nanoparticles to the tumor and once in it, a local hyperthermia process has been boosted using NIR radiation. This local hyperthermia has killed the tumor cells. J.ExtracellVesicles.2022;11:e12193.2) Pt nanoparticles have been encapsulated iin exosomes to mimic the therapeutic behavior of the drug cisplatin. They have been transported to the tumor and the therapeutic efficiency was as good as the free drug, but much less side effects. J.Nanobiotechnol.20,473(2022).